COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Bonnie Ky, Douglas L. Mann

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

Original languageEnglish
Pages (from-to)254-269
Number of pages16
JournalJACC: CardioOncology
Issue number2
StatePublished - Jun 2020


  • ACE2
  • COVID-19
  • SARS-CoV-2
  • clinical trials
  • renin angiotensin system


Dive into the research topics of 'COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities'. Together they form a unique fingerprint.

Cite this